Skip to main content
. 2020 Jun 10;109:104849. doi: 10.1016/j.oraloncology.2020.104849

Table 3.

Survival Outcomes for Patients Undergoing Either Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Oral Cavity Squamous Cell Carcinoma.

First Author Stage
 n*** T (%)
 N (%)
 Neoadjuvant Modality Radiation
 Chemotherapy Overall Survival (years, %)
I-II III-IV 1–2 3–4 0 1 2–3 Technique Dose (Gy)
 1 2 3 4 5
Median Range Dose per fraction
Bossi x** 198 41 59 57 27 16 CT none none none None Cisplatin 100 mg/m2 IV, 5-FU 1000 mg/m2 IV q21days × 3 cycles 55b
Chinn x** 72 24 76 26 22 51 CT none none none none Various: Cisplatin NOS or Carboplatin, 5-FU NOS q21days × 1 cycle then CRT with:
Cisplatin 100 mg/m2 IV q21days × 3 cycles;
1. Carbo AUC 6 IV q21days × 3 cycles		 47 42 32
Harada x 39 26 74 33 28 38 CCRT – 40 40 2 S-1 50–100 mg PO 5 days/week × 4 weeks 83.8 78.9
Hauswald x x 66 70 26 26 27 39 RT/CCRT IMRT 40 40 2 Platinum agent; immunotherapy (n = 1) 56.1c
Hirakawa x x 164 20 80 34 21 45 CT none none none none Cisplatin 80 mg/m2 IV day 6, 5-FU 800 mg/m2 IV days 1–5, q21days × 1 cycle 63.8
Inhestern x x 54 43 57 9 4 87 CT none none none none Docetaxel 30 mg/m2 IV , Cisplatin 40 mg/m2 IV, 5-FU 2000 mg/m2 IV days 1 and 8, q21days up to 3 cycles 97.3 responders73.7 non-responders
Irjala x x 10 20 80 60 10 30 RT/CCRT – – 63–65 Cisplatin 40 mg/m2 IV q7days × 4–6 cycles 60
Kies x** 23 57 43 43 – – CT – – – – Paclitaxel 175 mg/m2 IV, Ifosfamide 1000 mg/m2 IV days 1–3, Carbo AUC 6 IV q21-28 days × 3 cycles Crude overall survival: 48
Kina x 117 100 0 0 0 0 CT none none none none Met. Bleomycin 15 mg IV twice weekly, S-1 100 mg PO daily or UFT-E 450 mg PO TID × 3 weeks 90
Kirita x** 154 – – – – – CCRT – – – – Cisplatin 15 mg/m2 or Carbo 70–100 mg/m2 days 1–3 and peplomycin 5 mg/day or 5-FU 500–750 mg/day days 4–7, q28days × 2 cycles 83 79
Kreppel 2013 x** 139 41 59 20 17 63 CCRT – 39.6 39.6 1.8 Carbo 60 mg/m2/day IV × 5 days 45.5
Kreppel 2012 x** 151 29 71 – – – CCRT – 39.6 39.6 1.8 Carbo 70 mg/m2/day IV × 5 days 46.3
Lyu x 22 9 91 18 59 23 CT + RT – – – – Docetaxel 75 mg/m2 IV, cisplatin 75 mg/m2 IV, 5-FU 750 mg/m2 IV days 1–5, q21days × 2 cycles 67.2
Mucke x x 926 68 32 60 17 23 CCRT EBRT 20 2 Cisplatin 12.5 mg/m2 IV × 5 days during first week of RT 85.3 68.6
Myers x 70 – – – – – CT + RT/CCRT – 68 68 1.2 Platinum agent/Taxane +/- 5-FU; CTX 31.1
Sadighi x 24 – – – – – CT none none none none Docetaxel 70–80 mg/m2 IV Cisplatin 60 mg/m2 IV, 5-FU 750 mg/m2 IV × 5 days × 2–3 cycles 46.5c 23c
Zhong 2015 x x 256 26 74 43 37 20 CT none none none none Docetaxel 75 mg/m2 IV, Cisplatin 75 mg/m2 IV, 5-FU 750 mg/m2 IV on days1-5 q21days × 2 cycles 61.1c

‘-‘ not reported. 2D = Conventional two-dimensional radiation; 3DC = Three-dimensional conformational radiation therapy; 5-FU = 5-fluorouracil, Carbo = Carboplatin, CT = Chemotherapy, CTX = Cetuximab, CRT = chemoradiotherapy; EBRT = External Beam Radiation Therapy, IMRT = Intensity-modulated radiation therapy, Met. = Metronomic, RT = Radiotherapy, S-1 = oral 5-FU, UFT-E = oral 5-FU

aoverall survival for matched cohort

*

obtained from SEER database which does not capture chemotherapy

**

stage 2–4

***

total study cohort, not just those receiving CRT/RT

b

obtained from Lictra et al.

c

obtained from digitization of Kaplan-Meier curves